These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27324506)

  • 1. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
    Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
    Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
    Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
    Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
    Ayalasomayajula S; Pan W; Han Y; Yang F; Langenickel T; Pal P; Zhou W; Yuan Y; Rajman I; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):309-318. PubMed ID: 27245340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
    Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
    Clin Pharmacokinet; 2017 Dec; 56(12):1461-1478. PubMed ID: 28417439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
    Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
    Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
    Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
    J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
    Kulmatycki KM; Langenickel T; Ng WH; Pal P; Zhou W; Lin TH; Rajman I; Chandra P; Sunkara G
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):728-739. PubMed ID: 28737127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
    Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
    Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
    Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
    J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
    Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
    Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.
    Ayalasomayajula S; Schuehly U; Pal P; Chen F; Zhou W; Sunkara G; Langenickel TH
    Br J Clin Pharmacol; 2018 May; 84(5):926-936. PubMed ID: 29318651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
    Gan L; Jiang X; Mendonza A; Swan T; Reynolds C; Nguyen J; Pal P; Neelakantham S; Dahlke M; Langenickel T; Rajman I; Akahori M; Zhou W; Rebello S; Sunkara G
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):27-39. PubMed ID: 27119576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
    Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
    Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
    Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.